menu search

AMTI / Applied Molecular Transport to Report Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis

Applied Molecular Transport to Report Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis
- Live Conference Call and Webcast on Monday, April 25, 2022, at 8:30 a.m. ET (5:30 a.m. PT) Read More
Posted: Apr 24 2022, 13:00
Author Name: GlobeNewsWire
Views: 110852

AMTI News  

What Makes Applied Molecular Transport Inc. (AMTI) a New Buy Stock

By Zacks Investment Research
March 14, 2023

What Makes Applied Molecular Transport Inc. (AMTI) a New Buy Stock

Applied Molecular Transport Inc. (AMTI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects more_horizontal

Is Applied Molecular Transport (AMTI) Stock Outpacing Its Medical Peers This Year?

By Zacks Investment Research
February 8, 2023

Is Applied Molecular Transport (AMTI) Stock Outpacing Its Medical Peers This Year?

Here is how Applied Molecular Transport Inc. (AMTI) and Edwards Lifesciences (EW) have performed compared to their sector so far this year. more_horizontal

Applied Molecular Transport to Report Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis

By GlobeNewsWire
April 24, 2022


Search within

Pages Search Results: